7-amino-4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-methyl-2,3-dihydro-1H-isoindol-1-one → 7-amino-4-(1-{[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}-1H-pyrazol-4-yl)-2-methyl-2,3-dihydro-1H-isoindol-1-one

Participants

Reaction Steps

Prepared analogously to Compound 1C replacing Compound 1D with 4-(1-{[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-nitro-2,3-dihydro-1H-isoindol-1-one (Compound 5D, 1.96 g) to afford 1.03 g of the desired product (90%). 1H NMR (400 MHz, DMSO-d6) δ 7.96 (d, J=0.5 Hz, 1H), 7.75 (d, J=0.8 Hz, 1H), 7.43 (d, J=8.3 Hz, 1H), 6.62 (d, J=8.3 Hz, 1H), 6.07 (s, 2H), 4.38-4.47 (m, 3H), 4.24 (dd, J=1.4, 5.7 Hz, 2H), 4.01 (dd, J=6.3, 8.6 Hz, 1H), 3.78 (dd, J=5.7, 8.5 Hz, 1H), 3.03 (s, 3H), 1.24-1.35 (m, 6H). MS (ESI): m/z 343.15 [M+H]+. UPLC: tR=1.09 min (UPLC-TOF: polar—3 min).

Provenance & Evidence